miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Molecular Therapy2015Vol. 23(11), pp. 1748–1758
Citations Over TimeTop 10% of 2015 papers
Heba Khella, Henriett Butz, Qiang Ding, Fabio Rotondo, Kenneth Evans, Peter Kupchak, Moyez Dharsee, Ashraf Latif, Maria Pasic, Evi Lianidou, Georg A. Bjarnason, George M. Yousef
Related Papers
- → Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma—Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study(2016)36 cited
- → Improvement of Psoriasis During Sunitinib Therapy for Renal Cell Carcinoma(2010)33 cited
- → Ischaemic stroke in a patient on sunitinib: Figure 1(2010)6 cited
- → Sunitinib in Patients with Metastatic Renal Cell Carcinoma with Favorable Risk: Be Aware of PD-L1 Expression(2024)3 cited
- → Sunitinib Versus Interferon Alfa in Metastatic Renal Cell Carcinoma(2021)3 cited